(VIANEWS) - Masimo Corporation (MASI), Quidel (QDEL), CBAK Energy Technology (CBAT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Masimo Corporation (MASI)
88.5% sales growth and 14.71% return on equity
Masimo Corporation designs, produces, and sells noninvasive monitoring technology and solutions for hospital automation worldwide. Masimo Signal Extract Technology (SET) pulseoximetry is offered by the company. It offers measure-through motion pulse oximetry and low pulse oximetry monitoring. This addresses some of the limitations inherent in conventional pulse oximetry. Masimo Rainbow SET Platform also offers noninvasive monitoring of hemoglobin, such as oxygen saturation, pulse rate and perfusion index. It calculates the oxygen content and reserve index. SedLine brain function technology is offered by the company. It measures brain activity using EEG signals. Capnography products include gas monitors and external gas analyzers. Integrated modules and handheld capsnographs and capnometers. There are also capnography sampling lines. O3 regional oxygenmetry can be used to determine tissue oxygen saturation. Masimo Hospital Automation Platform includes Patient SafetyNet and surveillance; Kite; UniView, Replica; UniView: 60; and MyView. It offers coronavirus 2019 response, telehealth solutions and connectivity devices. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was founded in Irvine, California in 1989.
Masimo Corporation's sales growth this year is expected to be 62.8% and 18% for next year.
Year-on-year quarterly revenue growth grew by 85.3%, now sitting on 1.5B for the twelve trailing months.
Volume
Today's last reported volume for Masimo Corporation is 204826 which is 76% below its average volume of 853711.
Masimo Corporation's sales growth for the next quarter is 88.5%. The company's growth estimates for the ongoing quarter and the next is a negative 2.1% and 4.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.71%.
Volatility
Masimo Corporation's last day, last week, and last month's current intraday variation average was 1.80%, 1.96%, and 2.60%, respectively.
Masimo Corporation's highest amplitude of average volatility was 4.05% (day), 3.20% (last week), and 3.50% (last month), respectively.
Masimo Corporation's Stock Yearly Top and Bottom Value
Masimo Corporation's stock is valued at $145.03 at 16:22 EST, way under its 52-week high of $305.21 and way higher than its 52-week low of $112.07.
Masimo Corporation's Moving Average
Masimo Corporation's value is above its 50-day moving average of $143.95 and way below its 200-day moving average of $179.60.2. Quidel (QDEL)
22.8% sales growth and 51.53% return on equity
QuidelOrtho Corporation offers a variety of in vitro diagnostics products around the world. Its products include point-of care tests for critical heart health, infectious diseases and autoimmune biomarkers. The company also offers clinical and at home COVID-19 detection products. The company offers visually-readable lateral flow products for infectious diseases and reproductive health, as well as direct fluorescent antibodies in infectious illness and virology. It also produces fluorescent immunoassays with a special focus on bone, complement, and other markets. It was established in San Diego in 1979.
Quidel's sales growth this year is expected to be 64.5% and a negative 9.3% for next year.
Year-on-year quarterly revenue growth grew by 167%, now sitting on 2.33B for the twelve trailing months.
Volume
Today's last reported volume for Quidel is 330202 which is 53.88% below its average volume of 716049.
Quidel's sales growth for the next quarter is 22.8%. The company's growth estimates for the current quarter and the next is 309.3% and negative -81.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.53%.
Volatility
Quidel's last day, last week, and last month's current intraday variation average was 4.92%, 2.15%, and 2.40%, respectively.
Quidel's highest amplitude of average volatility was 4.57% (day), 3.32% (last week), and 3.57% (last month), respectively.
Quidel's Stock Yearly Top and Bottom Value
Quidel's stock is valued at $78.58 at 16:22 EST, way below its 52-week high of $180.06 and higher than its 52-week low of $77.32.
Quidel's Moving Average
Quidel's value is way below its 50-day moving average of $93.34 and way under its 200-day moving average of $106.96.3. CBAK Energy Technology (CBAT)
20.5% sales growth and 26.01% return on equity
Through its subsidiaries, CBAK Energy Technology, Inc. develops, produces, and markets lithium batteries throughout Mainland China, America, Europe, Taiwan, Israel, Taiwan, and the rest of the world. The company's products can be used for a variety of purposes, such as electric vehicles like electric cars and electric buses and hybrid electric cars or buses. It also makes light-electric vehicles which include electric bikes, motors and sight-seeing vehicles. CBAK Energy Technology, Inc. was previously known as China BAK Battery, Inc. CBAK Energy Technology, Inc. is located in Dalian, China.
CBAK Energy Technology's sales growth this year is anticipated to be 22.3% and 14.9% for next year.
Year-on-year quarterly revenue growth grew by 856.8%, now sitting on 173.91M for the twelve trailing months.
Volume
Today's last reported volume for CBAK Energy Technology is 208817 which is 49.73% below its average volume of 415395.
CBAK Energy Technology's sales growth is a negative 0% for the ongoing quarter and 20.5% for the next. The company's growth estimates for the current quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.01%.
Volatility
CBAK Energy Technology's last day, last week, and last month's current intraday variation average was 3.97%, 2.73%, and 3.80%, respectively.
CBAK Energy Technology's highest amplitude of average volatility was 5.56% (day), 5.14% (last week), and 7.57% (last month), respectively.
CBAK Energy Technology's Stock Yearly Top and Bottom Value
CBAK Energy Technology's stock is valued at $1.26 at 16:22 EST, way under its 52-week high of $3.57 and way higher than its 52-week low of $0.92.
CBAK Energy Technology's Moving Average
CBAK Energy Technology's value is under its 50-day moving average of $1.27 and under its 200-day moving average of $1.32.4. Marriot Vacations Worldwide Corporation (VAC)
15.5% sales growth and 4.89% return on equity
Marriott Vacations Worldwide Corporation is a vacation company that develops, markets and sells vacation ownership products and other related products. The company operates in two distinct segments: Vacation Ownership, Exchange & Third-Party Management. It manages the vacation ownership of related products and services under the Marriott Vacation Club and Grand Residences by Marriott brands. It markets and develops vacation ownership products and other related products under the The Ritz-Carlton destination club brand. The company also holds rights to market and develop residential ownership products under The Ritz-Carlton Residences. The company owned approximately 100 properties across the United States, as well as 12 additional countries and territories. It sells its luxury tier vacation ownership products through an extensive network of resort-based and off-site sales outlets. Marriott Vacations Worldwide Corporation was established in Orlando, Florida in 1984.
Marriot Vacations Worldwide Corporation's sales growth this year is anticipated to be 19.6% and 7.4% for next year.
Year-on-year quarterly revenue growth grew by 46%, now sitting on 2.99B for the twelve trailing months.
Volume
Today's last reported volume for Marriot Vacations Worldwide Corporation is 322516 which is 26.52% below its average volume of 438975.
Marriot Vacations Worldwide Corporation's sales growth for the next quarter is 15.5%. The company's growth estimates for the current quarter and the next is 167.1% and 57.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.89%.
Volatility
Marriot Vacations Worldwide Corporation's last day, last week, and last month's current intraday variation average was 3.72%, 2.45%, and 1.72%, respectively.
Marriot Vacations Worldwide Corporation's highest amplitude of average volatility was 4.40% (day), 2.40% (last week), and 2.35% (last month), respectively.
Marriot Vacations Worldwide Corporation's Stock Yearly Top and Bottom Value
Marriot Vacations Worldwide Corporation's stock is valued at $145.17 at 16:22 EST, way under its 52-week high of $174.74 and way above its 52-week low of $110.08.
Marriot Vacations Worldwide Corporation's Moving Average
Marriot Vacations Worldwide Corporation's value is way higher than its 50-day moving average of $131.57 and under its 200-day moving average of $149.54.5. Eli Lilly and Company (LLY)
15.1% sales growth and 74.02% return on equity
Eli Lilly and Company develops and markets pharmaceutical products for human use worldwide. Basaglar is available, as well as Humalog Mix 75/25 and Humalog U100. Humalog U200 and Humalog Mix 50/50. It also offers insulin lispro and insulin lispro prosamine. Insulin lispro 75/25 and Humulin 70/30 and Humulin N and Humulin R for diabetics. Jardiance and Trulicity are offered for type 2. Alimta is available for the treatment of non-small-cell lung cancer. Olumiant is available for rheumatoid arthritis; Taltz can be used for plaque psoriasis and psoriatic arthritis. Cymbalta is available for depression, diabetes peripheral neuropathic, anxiety disorder and fibromyalgia; Emgality can prevent migraines and treat episodic cluster headaches; Zyprexa can be used for bipolar disorder and maintenance. Bamlanivimab is available for COVID-19, as well as etesevimab and Bebtelovimab. Cialis can be used for benign prostatic hyperplasia and erectile dysfunction. Forteo treats osteoporosis. It has partnerships with Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc.
Eli Lilly and Company's sales growth this year is expected to be 10.8% and 5.2% for next year.
Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 29.32B for the twelve trailing months.
Volume
Today's last reported volume for Eli Lilly and Company is 1481730 which is 43.93% below its average volume of 2642650.
Eli Lilly and Company's sales growth is a negative 0% for the ongoing quarter and 15.1% for the next. The company's growth estimates for the current quarter and the next is 5% and 11.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 74.02%.
Volatility
Eli Lilly and Company's last day, last week, and last month's current intraday variation average was 0.70%, 1.58%, and 1.60%, respectively.
Eli Lilly and Company's highest amplitude of average volatility was 1.57% (day), 2.77% (last week), and 2.47% (last month), respectively.
Eli Lilly and Company's Stock Yearly Top and Bottom Value
Eli Lilly and Company's stock is valued at $315.03 at 16:22 EST, below its 52-week high of $335.33 and way above its 52-week low of $220.20.
Eli Lilly and Company's Moving Average
Eli Lilly and Company's worth is under its 50-day moving average of $315.22 and way above its 200-day moving average of $280.84.6. J & J Snack Foods Corp. (JJSF)
11.1% sales growth and 7.47% return on equity
J & J Snack Foods Corp. produces, markets and distributes a variety of nutritional snacks and drinks to the retail and food service industries in Canada, Mexico and the United States. The company operates three business segments, Food Service, Retail Supermarkets and Frozen Beverages. Soft pretzels are available under the following brands: SUPERPRETZEL PRETZEL FILLERS PRETZELFILS GOURMETTWISTS. MR. TWISTER. SOFT PRETZEL BITES. SOFTSTIX. SOFT PRETZEL BUNS. TEXAS. The company also offers frozen desserts and juices under the LUIGI’S, WHOLE FLRUIT, PHILLYSWIRL, SOURPATCH, ICEE and MINUTE MAD brands. It offers churros and dough-enrobed hand products under both the SUPREME STUFFERS, SWEET STUFFERS, and BRAUHAUS brands. The company also offers baked products such as cookies, fig, fruit bars, cakes, roll, crumb and muffins. J & J Snack Foods Corp. distributes their products via a network made up of independent distributors and direct sales representatives. It was established in 1971. The headquarters are located in Pennsauken in New Jersey.
J & J Snack Foods Corp.'s sales growth this year is expected to be 14.6% and 8.6% for next year.
Year-on-year quarterly revenue growth grew by 9.9%, now sitting on 1.25B for the twelve trailing months.
Volume
Today's last reported volume for J & J Snack Foods Corp. is 43338 which is 51.14% below its average volume of 88707.
J & J Snack Foods Corp.'s sales growth is a negative 0% for the present quarter and 11.1% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 33.8% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.47%.
Volatility
J & J Snack Foods Corp.'s last day, last week, and last month's current intraday variation average was 1.03%, 0.86%, and 1.39%, respectively.
J & J Snack Foods Corp.'s highest amplitude of average volatility was 1.70% (day), 1.83% (last week), and 2.33% (last month), respectively.
J & J Snack Foods Corp.'s Stock Yearly Top and Bottom Value
J & J Snack Foods Corp.'s stock is valued at $149.03 at 16:22 EST, way under its 52-week high of $165.78 and way above its 52-week low of $117.45.
J & J Snack Foods Corp.'s Moving Average
J & J Snack Foods Corp.'s worth is higher than its 50-day moving average of $142.44 and above its 200-day moving average of $146.01.7. J.B. Hunt Transport Services (JBHT)
10.8% sales growth and 30.72% return on equity
J.B. Hunt Transport Services, Inc. offers surface transport, logistics, and delivery services throughout North America. The company operates in five segments: Intermodal, Dedicated Contract Services(DCS), Integrated Capacity Solutionss (ICS), Final Mile Servicess (FMS), Truckload (JBT). Intermodal freight solutions are offered by the JBI segment. The JBI segment operates 104,973 pieces company-owned tracking equipment, owns and keeps its chassis fleet consisting of 85,649 units, and has a fleet that includes 5,612 company-owned tractor, 582 contractor trucks and 6,943 drivers. It develops and implements transportation supply chains that are supported by various transport networks. It owned 11,139 trucks and 544 trucks from customers, as well 6 contract trucks. It also owns 21,069 pieces of trailing equipment, and 7,753 trailers owned by customers. The ICS segment offers freight brokerage and transport logistics solutions. It includes flatbed, refrigerated and expedited transportation, dry-van, intermodal and intermodal transportation solutions, an online multimodal marketplace, logistics management, and logistic outsourcing for customers. FMS offers delivery services via 1,272 company trucks and 272 customer trucks. There are also 19 independent contractors trucks and 1,036 pieces of trailing equipment owned by the customers. JBT provides dry van freight services using tractors or trailers that operate over roads and highways via 734 company-owned tractor and 11172 company owned trailers. The company also arranges the transport of general merchandise, special consumer items, appliances and forest products. It also offers food, beverages, soaps and cosmetics as well as automotive parts, electronic products, agriculture products and chemicals. Lowell is the headquarters of this company, which was founded in 1961.
J.B. Hunt Transport Services's sales growth this year is anticipated to be 22.9% and 3% for next year.
Year-on-year quarterly revenue growth grew by 31.9%, now sitting on 13.97B for the twelve trailing months.
Volume
Today's last reported volume for J.B. Hunt Transport Services is 410096 which is 40.8% below its average volume of 692758.
J.B. Hunt Transport Services's sales growth for the next quarter is 10.8%. The company's growth estimates for the present quarter and the next is 30.9% and 9.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.72%.
Volatility
J.B. Hunt Transport Services's last day, last week, and last month's current intraday variation average was 2.48%, 1.72%, and 1.35%, respectively.
J.B. Hunt Transport Services's highest amplitude of average volatility was 2.17% (day), 3.39% (last week), and 2.47% (last month), respectively.
J.B. Hunt Transport Services's Stock Yearly Top and Bottom Value
J.B. Hunt Transport Services's stock is valued at $174.02 at 16:22 EST, way under its 52-week high of $218.18 and way higher than its 52-week low of $153.92.
J.B. Hunt Transport Services's Moving Average
J.B. Hunt Transport Services's worth is below its 50-day moving average of $176.64 and below its 200-day moving average of $184.22.8. Intuitive Surgical (ISRG)
7.5% sales growth and 12.66% return on equity
Intuitive Surgical, Inc. designs, produces, and markets products to enable healthcare professionals and physicians to improve the access and quality of minimally invasive medical care both in the United States, as well as internationally. It offers two products: the da Vinci Surgical System, which allows complex surgery to be performed using a minimally invasive method; and the Ion Endoluminal System. This system extends the company's commercial offerings beyond just surgery. The company also offers a range of core instruments, energy and stapling products for surgical systems. It also offers progressive learning paths to help customers use its technology. Sunnyvale is the headquarters of this company, which was founded in 1995.
Intuitive Surgical's sales growth this year is expected to be 8.6% and 12.4% for next year.
Year-on-year quarterly revenue growth grew by 4%, now sitting on 5.96B for the twelve trailing months.
Volume
Today's last reported volume for Intuitive Surgical is 1006190 which is 49.12% below its average volume of 1977930.
Intuitive Surgical's sales growth for the next quarter is 7.5%. The company's growth estimates for the current quarter and the next is a negative 5.9% and negative -6.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.66%.
Volatility
Intuitive Surgical's last day, last week, and last month's current intraday variation average was 3.04%, 2.20%, and 1.69%, respectively.
Intuitive Surgical's highest amplitude of average volatility was 2.99% (day), 3.53% (last week), and 2.75% (last month), respectively.
Intuitive Surgical's Stock Yearly Top and Bottom Value
Intuitive Surgical's stock is valued at $202.29 at 16:22 EST, way below its 52-week high of $369.69 and above its 52-week low of $186.83.